CCTG 590 is a open-label study to evaluate the impact of therapy intensification with
Maraviroc (MVC) (a CCR5 inhibitor) to a stable suppressive HIV antiretroviral regimen on the
rate of CD4+ T-cell recovery and gene expression profiles. Patients on a stable first-line
HIV regimen with continued viral suppression and sub-optimal CD4+ T-cell counts will be
eligible for this study. Those who are found to be eligible will have MVC (dose-adjusted to
background HIV regimen) added to their current HIV regimen for 24 weeks. After the 24 week
intensification, the MVC will be discontinued, the original antiretroviral regimen will be
continued and the subjects will be followed for an additional 12 weeks.
The investigators hypothesize that MVC will improve the rate of CD4 recovery. This improved
CD4 recovery will be associated with favorable changes in gene expression profiles of genes
involved with CD4 maintenance and circulation.